Lariba, Jesusa F.
HRN: 08-40-55 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/04/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
08/04/2024
08/11/2024
IV
2.25
Q8
Uti
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes